Suppr超能文献

单中心最早可用的血管内移植物组件进行血管内动脉瘤修复后的 12 年结果。

Twelve-year outcomes after endovascular aneurysm repair using earliest available endograft components from a single center.

机构信息

Vascular/Endovascular Service, University College Hospital, London, United Kingdom.

出版信息

J Vasc Surg. 2010 Jul;52(1):49-54. doi: 10.1016/j.jvs.2010.02.257. Epub 2010 May 15.

Abstract

OBJECTIVES

Comprehensive long-term outcome data after endovascular aneurysm repair (EVAR) are scarce, although anecdotes of endograft failure in the early 1990s abound. The objective of this report is to provide comprehensive outcomes after EVAR performed with the earliest available endograft components. These were a home-made endograft (pre-expanded polytetrafluoroethylene [PTFE] fixed with giant Palmaz stents) and first-generation Talent endografts (World Medical, Sunrise, Fla).

METHODS

A prospectively recorded database of all cases undertaken at a tertiary referral center was retrospectively interrogated. Sex, age, types of endograft used, and fate of patient and endografts implanted between 10 and 15 years previously were studied. A literature search was undertaken to obtain data for long-term survival after EVAR and open surgery (OR).

RESULTS

There were 50 patients in total operated on between 1994 and 1998 of whom 43 were male. The median age was 73 years (54-93) at time of EVAR and 85 years (67-100) in the survivors at a median of 12 years later. There were 26 home-made (PTFE fixed with Palmaz stents) and 24 Talent endografts (World Medical). Thirty-day mortality was 4%, one death in a ruptured abdominal aortic aneurysm. Twenty-one (42%) survived for 12 years to the time of reporting. Of these, 6 have functioning home-made endografts, 8 have Talent endografts, and 8 (5 home-made and 3 Talent) survive after conversion to OR. Secondary interventions took place in 9 further patients. Of 27 late deaths, 1 suffered endograft sepsis, 20 died of cardio-respiratory causes and 6 died of cancer. The only report of more than a 10-year survival after OR was found in an e-publication from Sweden. The projected survival after 10 years was 40% for unruptured aneurysms. However, survival in the general population was higher at 60%.

CONCLUSIONS

Ten-year survival after EVAR parallels that of elective OR but is less than the general population. Although the rate of eventual conversion to open repair was high using this earliest available endograft technology, the aneurysm-related mortality was low, and both endografts remain functional for more than 10 years after placement.

摘要

目的

虽然 20 世纪 90 年代初就有血管内动脉瘤修复(EVAR)后内植物失败的传闻,但有关 EVAR 后综合长期结果的数据仍然很少。本报告的目的是提供最早可用的内植物组件进行 EVAR 后的综合结果。这些内植物组件包括自制内植物(预扩张聚四氟乙烯[PTFE]用 giant Palmaz 支架固定)和第一代 Talent 内植物(World Medical,Sunrise,Fla)。

方法

回顾性分析了在三级转诊中心进行的所有病例的前瞻性记录数据库。研究了 1994 年至 1998 年间植入的患者和内植物的性别、年龄、使用的内植物类型以及患者和内植物的结局。进行了文献检索,以获得 EVAR 和开放手术(OR)后长期生存的数据。

结果

共有 50 例患者在 1994 年至 1998 年间接受了手术,其中 43 例为男性。EVAR 时的中位年龄为 73 岁(54-93 岁),幸存者在 12 年后的中位年龄为 85 岁(67-100 岁)。26 例为自制(PTFE 用 Palmaz 支架固定),24 例为 Talent 内植物。30 天死亡率为 4%,1 例死于破裂的腹主动脉瘤。报告时,21 例(42%)存活 12 年。其中,6 例有功能的自制内植物,8 例有 Talent 内植物,8 例(5 例自制和 3 例 Talent)在转为 OR 后存活。另外 9 例患者进行了二次干预。在 27 例晚期死亡中,1 例死于内植物感染,20 例死于心肺原因,6 例死于癌症。唯一发现的瑞典电子出版物中,有一例 OR 后 10 年以上的生存报告。预计 10 年后未破裂动脉瘤的生存率为 40%。然而,一般人群的生存率更高,为 60%。

结论

EVAR 后 10 年的生存率与选择性 OR 相似,但低于一般人群。尽管使用这种最早可用的内植物技术,最终转换为开放修复的比例较高,但动脉瘤相关死亡率较低,并且两种内植物在放置后 10 年以上仍保持功能。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验